AYLA · Old Ayala, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Revenue | $692.0K | $3.51M | $3.71M |
| Cost of Revenue | $602.0K | $3.51M | $3.71M |
| Gross Profit | $90.0K | $0 | $0 |
| R&D | $27.85M | $29.94M | $22.41M |
| SG&A | $9.74M | $9.28M | $7.37M |
| Total Operating Expenses | - | $300.0K | - |
| D&A | $162.0K | $168.0K | $182.0K |
| Operating Income | ($37.50M) | ($39.22M) | ($29.78M) |
| Interest Expense | - | - | - |
| Income Tax | $584.0K | $776.0K | $425.0K |
| Net Income | ($38.01M) | ($40.25M) | ($30.15M) |
| EPS - Basic | ($2.80) | - | - |
| EPS - Diluted | ($2.80) | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash & Equivalents | $2.41M | $36.98M | $42.02M |
| Accounts Receivable | $234.0K | - | $681.0K |
| Inventory | - | - | - |
| Accounts Payable | $4.08M | $3.21M | $3.73M |
| Current Assets | $3.19M | $39.74M | $44.24M |
| Total Assets | $7.77M | $41.13M | $45.83M |
| Current Liabilities | $7.54M | $6.47M | $6.88M |
| Long-term Debt | - | - | - |
| Total Liabilities | - | - | - |
| Stockholders' Equity | ($1.10M) | $34.16M | $38.40M |
| Retained Earnings | ($149.15M) | ($111.14M) | ($70.89M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Cash Flow | ($34.51M) | ($38.36M) | ($27.54M) |
| Investing Cash Flow | ($2.0K) | ($5.0K) | $181.0K |
| Financing Cash Flow | ($103.0K) | $33.33M | $52.92M |
| CapEx | $2.0K | $5.0K | $45.0K |
| Free Cash Flow | ($34.51M) | ($38.36M) | ($27.59M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Profitability | |||
| Gross margin | 13.0% | 0.0% | 0.0% |
| Operating margin | -5419.5% | -1118.6% | -803.0% |
| EBITDA margin | -5396.1% | -1113.8% | -798.1% |
| Net margin | -5493.2% | -1148.1% | -813.0% |
| Free cash flow margin | -4987.3% | -1094.2% | -744.0% |
| FCF / Net income | 0.91 | 0.95 | 0.92 |
| R&D / Revenue | 4024.7% | 854.0% | 604.3% |
| SG&A / Revenue | 1407.8% | 264.6% | 198.8% |
| Effective tax rate | - | - | - |
| Return on assets | -489.3% | -97.9% | -65.8% |
| Return on equity | 3458.9% | -117.8% | -78.5% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 0.42 | 6.14 | 6.43 |
| Quick ratio | 0.42 | 6.14 | 6.43 |
| Cash ratio | 0.32 | 5.71 | 6.11 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | -7.07 | 1.20 | 1.19 |
| Liabilities / Assets | - | - | - |
| Efficiency | |||
| Asset turnover | 0.09 | 0.09 | 0.08 |
| Inventory turnover | - | - | - |
| Days sales outstanding | 123d | - | 67d |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | 2474d | 335d | 367d |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | - | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | -80.3% | -5.4% | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | 4.4% | -31.7% | - |
| Net income growth (YoY) | 5.6% | -33.5% | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | 10.0% | -39.1% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | - | -11.0% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Old Ayala against the 5 most active filers in the same SIC group.